IC 51

Drug Profile

IC 51

Alternative Names: IC-51; Ixiaro; Japanese-encephalitis-purified-inactivated-vaccine-Valneva; JE-PIV; Jeev; Jespect; Jeval

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VaccGen International LLC
  • Developer Adimmune Corporation; Biological E Limited; CSL; Valneva
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Japanese encephalitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Japanese encephalitis

Most Recent Events

  • 05 Oct 2018 Valneva receives approval from the US FDA for accelerated schedule of IC 51 for Japanese encephalitis (Prevention) (In Adults)
  • 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions
  • 02 Aug 2018 Valneva receives approval from Health Canada for the accelerated schedule of IC 51 for Japanese encephalitis (Prevention) for adult travellers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top